Study of Toujeo (insulin glargine) shows reduced risk of hypoglycemia in patients with type 2 diabetes- Sanofi

Sanofi announced new evidence from a real-world observational study demonstrating significantly less risk of documented hypoglycemia with similar blood sugar control after switching to Toujeo (insulin glargine 300 Units/mL) compared to switching to another basal insulin including Lantus (insulin glargine 100 Units/mL), Levemir (insulin detemir) and Tresiba (insulin degludec), in an at-risk population of senior adults (aged 65 years or older) with type 2 diabetes. In the DELIVER 3 study, patients switching to Toujeo were 57 percent less likely to experience hypoglycemia at 6-month follow-up than those who switched to another basal insulin, with similar glycemic control.

These findings are broadly consistent with Toujeo evidence from DELIVER 2, a retrospective observational study that included two matched cohorts of 1,827 (n=3,654) adults with type 2 diabetes using basal insulin who switched to either Toujeo or another basal insulin. DELIVER 2 showed 33 percent fewer hypoglycemic events after 6 months in a broader population of adults with type 2 diabetes, which contributed to an estimate of all-cause healthcare cost savings of up to approximately $2,000 per patient per year.

The results of the DELIVER 3 retrospective observational study comparing two cohorts were presented at the American Diabetes Association 77th Scientific Sessions Annual Meeting.